Replies to post #458788 on Anavex Life Sciences Corp (AVXL)

[tredenwater2]

This guy is spot on George. Thanks for the link. Not sure how many people he reaches with only 21 followers but this s what we will see after the peer reviewed paper and as we get closer to approval. Ut will be a COMPLETE reversal and a “uh duh” moment in history when time stands still as the shot will be heard around the world! Make your nickels and dimes now cause this is going up in the coming months.

Also Kudos to Dr. Missling for being steady at the helm during multiple storms.

Blessings

Tred

[kund]

Another delusional pumper. Check his record, he writes on SA under "The Political Economist".

In Jan 2023 he wrote "Approval for AVXL-2-73 looks inevitable...." In Nov 2023 "How soon Anavex's drug be approved..."

The entire WGT crowd full of conspiracy mindset, this company and drug is worthless because of clown ceo, who spends 364 days with model in Europe, he designed useless tiny trials using "Super Responder" buzzword.

[bb8675309]

$100 per share or $8 Billion MC is a cheap price with current drug trial results we know today. imo. Incredible...

[nidan7500]

GOOD NEWS starting to flow from new sources...nice to see...C'MON... show (. FDA SPEAK. "Proven by provision of objective evidence", ) showing us the way to get started REALLY making news..."Before vs After images are killer proof, even W/S & FDA can't screw THAT UP".

The European Union is currently working with Anavex to examine Blarcamesine’s clinical trial results and other factors for possible approval for use in combating Alzheimer’s Disease.

The U.S. FDA currently is not evaluating Blarcamesine for approval in the United States.

Today, Anavex Life Sciences CEO Christopher Missling discussed data from the Phase 2b/3 drug trial of Blarcamesine showing that the drug lowered the level of beta amyloid plaques in the brains of Alzheimer’s patients. This result was actually somewhat surprising, as, according to Dr. Missling Blarcamesine is designed to alter brain chemistry upstream from the production of beta-amyloid.

Unlike Biogen’s Lecanemab, Blarcamesine is not designed to clear beta-amyloid plaques from the brain.

The implication seems to be that Blarcamesine, working upstream, prevents the production of these plaques rather than clearing them out.

Another possible implication is that Blarcamesine helps the brain with autophagy — regulating itself and recycling cell parts. Dr. Missling has noted in the past that the drug is designed to help with autophagy.

Through autophagy, then, the brain may be clearing the plaques on its own, as spurred on by Blarcamesine.

In the conference call, Dr. Missling also noted that the drug trial demonstrated that Blarcamesine prevents brain shrinkage among Alzheimer’s patients. In fact, in my reading of the results, this was perhaps the most statistically significant finding of the entire drug trial.

When I say “brain shrinkage” I mean the loss of brain mass: losing millions of brain cells. I have seen this loss in my mother’s brain scans; my mother suffers from Alzheimer’s Disease.

Could the preservation of brain mass be an effect of the autophagy that

BREAKING: Anavex’s Blarcamesine reduces plaque in Alzheimer’s brains without dangerous side effects

From ST

https://medium.com/@irwinbooks/breaking-anavexs-blarcamesine-reduces-plaque-in-alzheimer-s-brains-without-dangerous-side-effects-df893e362a37